Alvotech (NASDAQ:ALVO) Q2 2023 Earnings Conference Call August 31, 2023 8:00 AM ET
Company Participants
Benedikt Stefansson - Director of IR & Global Communications
Robert Wessman - Chairman & CEO
Anil Okay - Chief Commercial Officer
Joel Morales - CFO
Conference Call Participants
Carl Byrnes - Northland Capital Markets
Thibault Boutherin - Morgan Stanley
Niall Alexander - Deutsche Bank
Andrew Baum - Citi
Operator
Welcome to the Second Quarter 2023 Earnings Call for Alvotech. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to introduce and hand the conference over to Mr. Benedikt Stefansson, Senior Director of Investor Relations and Global Communications at Alvotech. Please proceed.
Benedikt Stefansson
Thank you. Good morning to our U.S. audience and good afternoon to our listeners in Iceland, Europe and Asia. Yesterday evening the company issued a press release that can be found in the News section of our investor portal investors.alvotech.com. The release outlines key highlights related to our second quarter results. Additionally, presentation slides that cover our call today have been posted on our website in the Events section of investors.alvotech.com. We will be referring to these slides during our presentation today.
Our presentation materials and some of the statements that we make today may include forward-looking statements. These statements do not ensure future performance and are subject to risks and uncertainties that are outlined in company filings with the Securities and Exchange Commission and the NASDAQ Iceland Stock Exchange. These risks and uncertainties are inherently subject to risks, variability and contingencies, many of which are beyond Alvotech's control and could cause actual results to differ materially from forward-looking statements that are made.
With me on today's call are Robert Wessman, Chairman and CEO of Alvotech. Anil Okay, Chief Commercial Officer; Joel Morales, Chief Financial Officer; and Ming Li, Chief Strategy Officer.
With that, I would like to turn the call over to Robert Wessman, Founder, Chairman and CEO of Alvotech. Robert?
Robert Wessman
Thank you, Benedikt. Thank you all for joining us here today. Allow me to kick-off today’s discussion by sharing some pivotal update since our last public communication. To begin with, we have resubmitted interchangeable BLA for our proposed biosimilar to HUMIRA, also known as a AVT02. As a reminder, we have developed a high concentration formulation of adalimumab, which is the predominant form on the market today and we have met all requirements to secure interchangeability.